NCT06869473
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06869473
Title Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, As First-line Treatment for Recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients with a PD-L1 Combined Positive Score (CPS)>/=1=/<19. (AVEC-119)
Acronym AVEC-119
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gruppo Oncologico del Nord-Ovest
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA

Facility Status City State Zip Country Details
Ospedale Oncologico "A. Businco" ARNAS BROTSU NOT_YET_RECRUITING Cagliari CAGLIARI 09121 Italy Details
Azienda Ospedaliero-Universitaria Policlinico "G. Rodolico-S. Marco NOT_YET_RECRUITING Catania CATANIA 95123 Italy Details
Azienda Ospedaliero-Universitaria Careggi RECRUITING Florence FIRENZE 50134 Italy Details
Fondazione IRCCS Istituto Nazionale dei Tumori (INT) di Milano RECRUITING Milan Milano 20133 Italy Details
Irccs Humanitas Research Hospital NOT_YET_RECRUITING Rozzano Milano 20089 Italy Details
Irccs Fondazione G. Pascale RECRUITING Napoli Napoli 80131 Italy Details
AOU Luigi Vanvitelli NOT_YET_RECRUITING Napoli NAPOLI 80138 Italy Details
Azienda Ospedaliero-Universitaria Sant'Andrea NOT_YET_RECRUITING Roma roma 00189 Italy Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field